MedTrace Logo

Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

NCT04456075 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-07-02

No results posted yet for this study

Summary

Approximately 15% of patients with SARS-CoV-2 infection / COVID-19 develop a severe clinical course. This leads to hospitalization and potentially life threatening complications such as pneumonia and respiratory failure. Predictors for early detection and risk stratification are urgently needed. Moreover, only scarce information is available for long-term follow-up and late complications associated with infection. We therefore aimed to find predictors for severe courses of the novel disease as well as to establish strategies for therapeutic monitoring and follow-up.

Conditions

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Frederik Trinkmann, MD · Thoraxklinik at Heidelberg University

  • Felix JF Herth, MD · Thoraxklinik at Heidelberg University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04456075 on ClinicalTrials.gov